

50th Anniversary Celebration Collection

Special Section on Xenobiotic Receptors

The Function of Xenobiotic Receptors in Metabolic Diseases

Jinhang Zhang, Qingyi Jia, Yanping Li, and Jinhan He

Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy (J.Z., Y.L., J.H.) and Department of Endocrinology and Metabolism (Q.J.), West China Hospital, Sichuan University, Chengdu, Sichuan, China

Received January 30, 2022; accepted November 9, 2022

ABSTRACT

Metabolic diseases are a series of metabolic disorders that include obesity, diabetes, insulin resistance, hypertension, and hyperlipidemia. The increased prevalence of metabolic diseases has resulted in higher mortality and mobility rates over the past decades, and this has led to extensive research focusing on the underlying mechanisms. Xenobiotic receptors (XRs) are a series of xenobiotic-sensing nuclear receptors that regulate their downstream target genes expression, thus defending the body from xenobiotic and endotoxin attacks. XR activation is associated with the development of a number of metabolic diseases such as obesity, non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular diseases, thus suggesting an important role for XRs in modulating metabolic diseases. However, the regulatory mechanism of XRs in the context of metabolic disorders under different nutrient conditions is complex and remains controversial. This review

summarizes the effects of XRs on different metabolic components (cholesterol, lipids, glucose, and bile acids) in different tissues during metabolic diseases. As chronic inflammation plays a critical role in the initiation and progression of metabolic diseases, we also discuss the impact of XRs on inflammation to comprehensively recognize the role of XRs in metabolic diseases. This will provide new ideas for treating metabolic diseases by targeting XRs.

SIGNIFICANCE STATEMENT

This review outlines the current understanding of xenobiotic receptors on nutrient metabolism and inflammation during metabolic diseases. This work also highlights the gaps in this field, which can be used to direct the future investigations on metabolic diseases treatment by targeting xenobiotic receptors.

Introduction

Metabolic diseases represent a cluster of conditions that primarily result from excessive nutrient and metabolite [including but not limited to lipids, cholesterol, glucose, and bile acid (BA)] dysregulations (Rochlani et al., 2017). Over the past 20 years, more than 1 billion people have suffered from metabolic diseases related to the global

epidemic of obesity and type 2 diabetes (Eckel et al., 2005; Saklayen, 2018; Jeffery and Richardson, 2021). Metabolic diseases seriously affect quality of life and increase mortality risk when they cannot be effectively controlled. Therefore, further investigations examining the underlying mechanisms responsible for metabolic disorders will provide evidence for novel treatments.

Exogenous substances such as xenobiotics, pathogens, and food can interfere with intestinal homeostasis. In obesity and other metabolic abnormalities, chronic inflammation is a key contributor to insulin resistance and causes malfunctions in insulin-target organs (Hotamisligil, 2006; Kawai et al., 2021; Lee and Olefsky, 2021). Evidence suggests that exogenous substances promote systemic inflammation and are related to

This work received no external funding.

No author has an actual or perceived conflict of interest with the contents of this article.

dx.doi.org/10.1124/dmd.122.000862.

ABBREVIATIONS: ABCs, ATP-binding cassette family proteins; AHR, aryl hydrocarbon receptor; AHRR, aryl hydrocarbon receptor repressor; BA, bile acid; CAR, constitutive androstane receptor; Cpt1a, carnitine palmitoyl-transferase 1A; CYP, cytochrome P450; DEX, dexamethasone; EGCG, (-)-epigallocatechin-3-gallate; FA, fatty acid; Fasn, fatty acid synthase; G6Pase, glucose 6-phosphatase; GST, glutathione S-transferase; HFD, high-fat diet; I κ B α , nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha; LCA, lithocholic acid; LDL, low-density lipoprotein; LPS, lipopolysaccharide; LXR, liver X receptor; NAFLD, nonalcoholic fatty liver disease; NF- κ B, nuclear factor kappa B; OATP, organic anion transporting polypeptide; PCN, pregnenolone-16a-carbonitrile; PEPCK, phosphoenolpyruvate carboxykinase; PPAR γ , peroxisome proliferator-activated receptor γ ; PXR, pregnant X receptor; RXR, retinoid X receptor; SREBP1, sterol regulatory element binding transcription factor 1; SULT, sulphotransferase; TCPOBOP, 1,4-bis-[2-(3,5-dichloropyridyloxy)] benzene, 3,3',5,5'-tetrachloro-1,4-bis (pyridyloxy) benzene; TLR4, Toll-like receptor 4; UGT, uridine diphosphate glucuronosyltransferase; XR, xenobiotic receptor.

metabolic diseases (Di Tommaso et al., 2021). To defend from these exogenous substances, host cells express xenobiotic receptors (XRs) such as pregnant X receptor (PXR), constitutive androstane receptor (CAR), and aryl hydrocarbon receptor (AHR) that were originally considered to be receptors that were expressed by host cells to sense and defend against xenobiotics (Nieves et al., 2022). Numerous metabolites have been demonstrated to promote the expression of XRs and to exert metabolic functions through XRs activation. PXR is a member of the nuclear receptor superfamily that affects energy homeostasis and inflammatory bowel disease (Koutsounas et al., 2013). CAR can regulate the metabolism of glucose, lipids, and BAs involved in metabolic diseases (Daujat-Chavanieu and Gerbal-Chaloin, 2020). Moreover, AHR has also been demonstrated not only to play endogenous roles in natural physiology but also to be involved in the pathology of metabolic diseases and inflammation, thus suggesting a significant role for XRs in the context of metabolic diseases (Petriello et al., 2017). Here, we review the growing knowledge regarding the physiology of XRs in metabolism, focusing on the role of XRs in different nutrient metabolism processes during different metabolic diseases. Understanding the complex roles of XRs in metabolic diseases may shed light on improved treatments for these diseases.

The Overall View of the Xenobiotic-Sensing Receptors

XRs consist of a group of receptors that are capable of binding to xenobiotics and sensing endogenous and exogenous toxic byproducts (Mackowiak and Wang, 2016). XRs are capable of regulating the enzyme activity and transporters involved in drug metabolism (Cai et al., 2021). Upon ligand binding, XRs translocate to the nucleus and couple with the nuclear receptor retinoid X receptor (RXR), thus initiating transcription in cells to execute their functions. In addition to metabolizing xenobiotics, XRs can support normal tissue function by regulating their downstream target genes expression in different organs (Oladimeji and Chen, 2018). PXR, CAR, and AHR are major XRs that have been well studied. Here, we review ligands and their biology.

PXR and Its Ligands

PXR is a ligand-regulated nuclear receptor that is overexpressed in the liver and intestines. It modulates key steps of xenobiotic and endobiotic metabolism in enterohepatic tissues (Fiorucci et al., 2012). Like other nuclear receptors, PXR includes an N-terminal domain, a DNA-binding domain, a hinge region, and a ligand-binding domain (Cai et al., 2021). Therefore, PXR can bind to large-scale ligands and regulate the expression of downstream target genes. Activated PXR directly regulates its target genes expression, including cytochrome P450 (CYP), carboxylesterases, glutathione S-transferases (GSTs), glutathione peroxidase, ATP-binding cassette family proteins (ABCs), organic anion transporting polypeptides (OATPs), and estrogen sulfotransferase 1E1 (Xing et al., 2020).

PXR ligands can be divided into small-molecule chemicals, natural herbs, and endogenous biomolecules. The well-known agonist ligands of PXR contain rifampicin, dexamethasone (DEX), ritonavir, lovastatin, ritonavir, phenobarbital, clotrimazole, pregnenolone-16 α -carbonitrile (PCN), natural herb St. John's Wort, 5 β -pregnane-3,20-dione, estradiol, and lithocholic acid (LCA) (Satoru Kakizaki, 2011; Fiorucci et al., 2012; Brewer and Chen, 2016; Chai et al., 2016). A large number of agonist ligands activate PXR and exhibit species differences. For example, due to the low homology between mouse and human ligand-binding domains, rifampicin exhibits a high affinity for human PXR, while PCN is a potent agonist of mouse PXR (Kliwer et al., 1998; Xie et al., 2000; Cai et al., 2021). The calcium channel blocker felodipine was recently identified as a novel PXR agonist that can induce mouse PXR expression (Reddy and Nyunoya, 2021). Additionally, the activation of PXR through the process of ligand

binding exhibits tissue specificity. A recent study suggested that tributyl citrate, a Food and Drug Administration-approved plasticizer for food and pharmaceutical applications, is a selective and latent PXR agonist in both mice and humans. Interestingly, tributyl citrate only activates intestinal PXR and does not influence PXR activity in liver (Sui et al., 2015). With the gradual development of knowledge concerning the ocean, many studies have also identified a series of natural molecules isolated from marine organisms that possess a potent ability to bind to PXR (Carazo et al., 2019).

In addition to ligand-dependent activation, the post-translational modulation of PXR can also regulate its activity. Poly(ADP-ribosylation) and SUMOylation of PXR stimulates its activity by influencing PXR protein stability and dimerization (Cui et al., 2015; Priyanka et al., 2016; Wang, Xu et al., 2018). However, PXR phosphorylation, acetylation, and ubiquitination inhibit PXR activity by regulating its subcellular localization, coregulatory interaction, and degradation (Biswas et al., 2011; Rana et al., 2013; Cui et al., 2020; Hu et al., 2020). There is mounting evidence that noncoding RNAs, including long noncoding RNAs and microRNAs, modulate the function and expression of PXR post-transcriptionally (Smutny et al., 2021).

CAR and Its Ligands

CAR is also a member of the nuclear receptor superfamily (also known as NR1I3) that is mainly expressed in the liver (di Masi et al., 2009). CAR was discovered as a XR for both endogenous and exogenous ligands and participates in drug and energy metabolism and systematic inflammation. CAR is located in the cytoplasm and shuttles into the nucleus when activated (Modica et al., 2009). Once CAR is activated, it dephosphorylates and migrates to the nucleus, heterodimerizes with RXR, and recruits coactivator factors to allow for the transcription of its target genes (Oliviero et al., 2020). After activation, CAR increases the expression of the CYP phase I enzymes CYP2B, CYP3A, and CYP2C to detoxify drugs and external compounds (Li, Wang et al., 2021). CAR activation induces the expression of phase II enzymes, including uridine diphosphate glucuronosyltransferase (UGT) and sulphotransferase (SULT). Activation also increases the expression of uptake and efflux transporters such as multidrug resistance mutation 1, multidrug resistance proteins, and OATPs (Li et al., 2015).

Currently, large amounts of compounds have been confirmed as CAR ligands that activate or suppress CAR activity, and these range from synthetic compounds to natural products. Ligands activating human CAR include 6-(4-chlorophenyl) imidazo [2,1-b] thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl) oxime, phenobarbital, androstanol, valproic acid, efavirenz, and flavonoids (Cervený et al., 2007; Cherian et al., 2015; Bae et al., 2021). The compounds 1,4-bis-[2-(3,5-dichloropyridyloxy)] benzene, 3,3',5,5'-tetrachloro-1,4-bis (pyridyloxy) benzene (TCPOBOP), phenobarbital, androstanol, paclitaxel, and diallyl sulfide are ligands that activate murine CAR (Fisher et al., 2007; Goettel et al., 2020; Bhushan et al., 2021; Gao et al., 2021). Phenobarbital and androstanol can stimulate both murine and human CAR. Endogenous molecules, including steroids (androstanes, estrogens, and progestins), cholesterol metabolites, bilirubin, and BAs, have also been confirmed as CAR ligands (Küblbeck et al., 2020).

CAR has been demonstrated to shares several common ligands with PXR such as phenobarbital and 5 β -pregnane-3,20-dione. Interestingly, clotrimazole, which is a PXR activator, behaves as a CAR antagonist and exhibits an inverse activity between the two receptors (Moore et al., 2000). Previous investigations have suggested that CAR is activated via two pathways that are ligand-dependent and ligand-independent. Cytoplasmic retention of CAR is modulated by upstream phosphorylation cascades and cytoplasmic chaperones that are necessary for CAR activation (Yan J. et al., 2015). The molecular target of phenobarbital induction has now been confirmed as phosphorylation at threonine 38 of

CAR, and this dissociates CAR from the promoter and exports it back to the cytoplasm (Negishi, 2017).

Proteasomal inhibition interrupted CAR function, inhibits CAR nuclear trafficking, disrupts CAR interaction with coactivators in nuclear, and inhibits the induction of CAR target gene responses, and this leads to the accumulation of ubiquitinated human CAR (Chen et al., 2014; Daujat-Chavanieu and Gerbal-Chaloin, 2020). These findings suggest that CAR activity is not only influenced by ligand interactions but also by post-transcriptional modification.

AHR and Its Ligands

AHR is a member of the basic helix–loop–helix superfamily of transcription factors and is activated by ligands (Murray et al., 2014). AHR binds to several factors (embracing hsp90, AIP/XAP2, and p23) within the cytoplasm. Binding of AHR ligands leads to the nuclear translocation of the bound receptor complex, and this further activates or suppresses downstream target gene expression (Safe et al., 2020). These genes are related to oxidative balance, endocrine homeostasis, and diverse metabolic and immunologic progression (Goya-Jorge et al., 2020). The key downstream target genes of AHR are primarily ligand-metabolizing enzymes (CYP1A and CYP1B), immunoregulatory factors, and growth factors (IL-10, arginase 1, IL-6, IL-22, and vascular endothelial growth factor) (Shinde and McGaha, 2018). AHR participates in inflammatory responses, drug metabolism, and barrier homeostasis by regulating its downstream target genes.

AHR is a sensitive sensor for small molecules and endogenous and exogenous xenobiotics such as dioxins, microbial bioproducts, phytochemicals, and tryptophan-products (Furue et al., 2019). The canonical AHR agonist ligands include 2,3,7,8-tetrachlorodibenzo-p-dioxin, 5,11-dihydroindolo[3,2-b] carbazole-12-carbaldehyde, 2-(10-H-indole-3-carbonyl) thiazole-4-carboxylic acid methyl ester, tryptophan metabolites such as kynurenine and other gut microbial products, and leukotrienes (Shinde and McGaha, 2018; Safe et al., 2020). AHR antagonists include quercetin, resveratrol from the diet, and synthetic compounds such as CH223191, 3',4'-dimethoxyflavone, 3'-methoxy-4'-nitroflavone, and others (Shinde and McGaha, 2018). Recently, the novel small molecule tapinarof was identified as a therapeutic ligand for AHR and has been used for psoriasis and atopic dermatitis treatment in clinical practice (Bissonnette et al., 2021).

In addition to regulating its activity, several ligands have also been confirmed as regulators of AHR expression, containing endogenous metabolites such as 5,11-dihydroindolo[3,2-b] carbazole-12-carbaldehyde and indoxyl sulfate and also extensively used drugs such as omeprazole and leflunomide and dietary compounds such as quercetin (Stejskalova et al., 2011; Goya-Jorge et al., 2020; Kim, Jee et al., 2021; Rey-Bedon et al., 2022). In the AHR signaling pathway, the AHR repressor (AHRR) competes with AHR to prevent AHR from binding to the xenobiotic-response element (Oshima et al., 2009). Investigations have confirmed that AHRR post-translational modifications, containing SMUOylation, demethylation, and DNA methylation, can regulate the function of AHRR, and this further influences the activation of AHR signaling (Oshima et al., 2009; Philibert et al., 2012; Tian et al., 2017). Thus, AHR signaling activation can be divided into three isoforms that include stimulation by ligand binding, regulation of AHR expression, and AHR post-translational modification.

Previous studies have revealed that XRs play a vital role in maintaining tissue homeostasis and defending against toxicants by binding to ligands to further induce their downstream target gene expression. Their ligands include a series of endogenous substances and xenobiotics derived from internal synthetic compounds, natural products, and toxic substances. As PXR and CAR belong to the same superfamily, they share common ligands that can activate the two receptors

simultaneously. Ligand stimulation also exhibits differences in specific species and tissues, thus suggesting a complex function. In the future, the complex functions and specific conditions should be considered before considering ligands of XRs as treatment drugs.

PXR in the Context of Metabolic Disease

As a xenobiotic-sensing nuclear receptor that modulates the expression of drug metabolism-related enzymes and transporters, PXR can be regulated by various factors, containing pharmaceuticals, nutrients, and dietary and environmental factors. Most of these factors are closely associated with metabolic diseases (Ma et al., 2008; Sultana et al., 2021). Numerous studies have confirmed that PXR plays a vital role in regulating obesity, insulin resistance, nonalcoholic fatty liver disease (NAFLD), and cardiovascular diseases (He et al., 2013; Zhou, 2016; Sayaf et al., 2021). Moreover, PXR activation has been observed to regulate glucose, lipid, BA metabolism, and other important components of metabolic diseases. PXR can regulate inflammatory responses that are an important component of metabolic diseases. Here, we summarize the functional role of PXR in the context of nutrient metabolism and inflammation during metabolic diseases.

Functional Roles of PXR in Lipid Homeostasis

Increased lipid levels largely contribute to the development of atherosclerotic cardiovascular disease, fatty liver, and insulin resistance (Li, Yeh et al., 2018; Chen, Chen et al., 2019). Lipid metabolism is often accompanied by complex physiologic processes. The liver is the core organ participated in lipid metabolism through de novo lipogenesis, catabolism of lipids (β -oxidation), lipid uptake, and secretion (Alves-Bezerra and Cohen, 2017; Geng et al., 2021). In addition to the liver, adipose tissue is not only responsible for sufficient lipid storage by lipogenesis but also for fatty acid (FA) availability by lipolysis that provides the substrate for energy metabolism via β -oxidation (Bódis and Roden, 2018). The regulatory circuits for fuel storage and oxidation in white and brown adipose tissue play a key role in systemic energy homeostasis. Circuit dysregulation is an important cause of metabolic diseases, including obesity, insulin resistance, chronic inflammation, and cardiovascular diseases (Chouchani and Kajimura, 2019). As PXR plays a complex role in lipid metabolism, we review previous studies examining the effects of PXR on lipid metabolism in the liver and adipose tissue.

The Effects of PXR on Liver Lipid Metabolism. The liver is the major organ participated in metabolic degradation of xenobiotics (Jetter and Kullak-Ublick, 2020). In liver samples from NAFLD patients, sterol regulatory element binding transcription factor 1 (SREBP1) and SREBP1 target genes have been demonstrated to be upregulated during steatohepatitis, whereas PXR protein levels were reduced, thus suggesting the role of PXR in lipogenesis during NAFLD (Bitter et al., 2015). An in vivo study suggested that pharmacological activation of PXR significantly increased the mRNA levels of the nuclear receptor peroxisome proliferator-activated receptor γ (PPAR γ) and two lipogenic enzymes that included stearyl CoA desaturase and FA elongase, with increased levels of hepatic triglycerides (Moreau et al., 2008; Zhang et al., 2013). In human hepatic cells, ligand-dependent activation and knockout of PXR promotes de novo lipogenesis and steatosis by inducing the SREBP1 pathway and aldo-keto reductase 1B10-mediated increase in acetyl-CoA carboxylase activity (Bitter et al., 2015). S14 is a thyroid-responsive gene that transduces nutrient-related and hormone-related signals to genes involved in liver lipogenesis (Kinlaw et al., 1995). Moreau et al. (2009) confirmed that PXR activation facilitates aberrant de novo lipogenesis via the S14 pathway activation in liver. Interestingly, 4-week-old male AKR/J mice were fed a high-fat diet (HFD) for 7 weeks with twice-weekly injections of PCN (50 mg/kg,

IP). PCN treatment reduced hepatic Srebp1 expression and FA synthase (Fasn) genes, and this further alleviated lipid deposition in the liver (Ma and Liu, 2012). (-)-Epigallocatechin-3-gallate (EGCG), a major component of green tea, was determined to activate PXR and inhibit lipogenesis (Srebp1, Fasn, and acetyl-CoA carboxylase 1) in a HFD and streptozotocin-induced type 2 diabetes model (Li, Li et al., 2018). However, further study is required to determine whether the roles of EGCG on lipogenesis are dependent on PXR activation.

For lipid β -oxidation, PCN treatment decreased carnitine palmitoyl-transferase 1A (Cpt1a) expression and serum 3-hydroxybutyrate levels (Nakamura et al., 2007). In PXR^{-/-} mice after HFD feeding, Cpt1a expression was markedly increased, and this was accompanied by enhanced liver mitochondrial β -oxidation (He et al., 2013). Investigation of this mechanism confirmed that PXR directly binds to FoxA2 and represses its activation of Cpt1a and Hmgcs2 promoters in the fasting liver, thus further inhibiting lipid β -oxidation in the liver (Nakamura et al., 2007). A free FA uptake transporter, CD36, is positively regulated by PPAR γ . Zhou et al. (2008) reported that PXR could directly regulate CD36 or through its activation of PPAR γ to thereby further accelerate liver lipid deposition and induce liver-specific hepatic steatosis and insulin resistance in a liver specific way. Numerous substrates regulate lipid metabolism that is dependent upon the activation of PXR such as trisacetyl phosphate, naturally occurring lignan sesamin, and the pyrethroid pesticide cis-bifenthrin (Xiang et al., 2018; Tai et al., 2019; Xiang and Wang, 2021). These findings suggest that both whole-body and liver PXR activation enhanced hepatic lipid accumulation and decreased serum 3-hydroxybutyrate by influencing lipid de novo lipogenesis, β -oxidation, and uptake. Interestingly, two studies have demonstrated different effects of PXR on lipid metabolism compared with others, and this may be due to the complex effects of PXR in nutrient metabolism during different metabolic diseases. Investigating the effects of PXR in specific states during metabolic diseases may help to provide a deeper understanding of the effect of PXR.

The Effects of PXR on Adipose Lipid Metabolism. The primary lipid metabolism pathways in adipose tissue are lipolysis and lipogenesis. Although adipose tissue plays a notable role in metabolic diseases, few studies have considered the role of PXR on lipid metabolism in adipose tissue, and this may be owing to the low expression of PXR in adipose tissue. Only one study revealed that PCN treatment of ARK/J mice on a HFD increased the expression of hormone-sensitive lipase, an enzyme known to hydrolyze triglycerides in mammalian adipose tissue and in brown adipose tissue (Zimmermann et al., 2004; Ma and Liu, 2012). In turn, adipose tissue elevated lipolysis could increase the FA level in the circulation, and this would translocate into the liver and dysregulate PXR, ultimately further developing insulin resistance and hepatic steatosis (Renu et al., 2019). Few reports have examined the regulatory role of PXR in adipose tissue, thus suggesting that PXR may exert few effects on lipid metabolism in adipose tissue considering its expression level. FAs from adipocytes may conversely regulate PXR activation.

Functional Roles of PXR in Glucose Homeostasis

Glucose is a major source of energy for the human body that is required to maintain homeostasis, which involves a balance between glucose production and utilization. Glucose metabolism disorders lead to severe metabolic diseases, including diabetes, fatty liver, and cardiovascular diseases (Chen, Chen et al., 2019). The liver is the major organ responsible for approximately 90% of the endogenously synthesized glucose production through gluconeogenesis and glycogenolysis (Moore et al., 2012). The sources of glucose synthesis include diverse factors including pyruvate, lactate, amino acids, and glycerol during fasting (Schutz, 2011). There are three key rate-limiting enzymes during gluconeogenesis: phosphoenolpyruvate carboxykinase (PEPCK) that catalyzes the decarboxylation and

phosphorylation of oxaloacetate to generate phosphoenolpyruvate; fructose 1,6-bisphosphatase that converts fructose 1,6-bisphosphate to fructose 6-phosphate; and glucose 6-phosphatase (G6Pase) that produces glucose from glucose 6-phosphate (Kirchner et al., 2008).

The role of PXR on glucose metabolism primarily depends on its target genes expression such as PEPCK, G6Pase, glucose transporter 2, and MDRs. Studies have demonstrated that prototypical PXR agonists PCN and rifampin administration results in increased glucose levels during oral glucose tolerance tests in humans and rats (Rysä et al., 2013). In contrast, upon HFD feeding, PXR ablation ob/ob mice exhibited significantly ameliorative glucose tolerance and decreased serum glucose levels during fasting and feeding, and this was accompanied by decreased hepatic PEPCK and G6Pase levels (He et al., 2013; Ling et al., 2016). In regard to the underlying mechanism of PXR in regulating gluconeogenesis, Kodama et al. (2007) reported that PXR suppressed G6Pase by binding to cAMP-response element-binding protein directly. FoxO1 and PXR reciprocally coregulate their target genes, thus modulating gluconeogenesis (Kodama et al., 2004). Additionally, ligand-activated PXR interferes with HNF-4 signaling through targeting the common coactivator PGC-1 during glucose metabolism (Bhalla et al., 2004). A recent study confirmed that low glucose stimulates PXR phosphorylation at Ser350 and further increases gluconeogenesis in human HepG2 cells, thus suggesting positive feedback between PXR and glucose metabolism (Gotoh et al., 2017). Interestingly, the expression of G6Pase and PEPCK was decreased in the livers of HFD-fed AKR/J mice treated with PCN, a PXR agonist, and this was accompanied by improved insulin sensitivity (Ma and Liu, 2012). Another study also reported that a major green tea component, EGCG, ameliorated glucose homeostasis and restrained gluconeogenesis (PEPCK and G6Pase) through direct or indirect activation of PXR in HFD-induced type 2 diabetes models (Li, Li et al., 2018).

PXR not only decreases glucose production but also influences glucose uptake and utilization in liver cells. Pretreatment with rifampicin and PCN markedly inhibited glucose uptake caused by decreased levels of glucose transporter 2, the primary glucose transporter in mammalian liver and wild-type mouse hepatocytes (Hassani-Nezhad-Gashti et al., 2018). The PXR activators rifampin and PCN could also decrease glucose consumption and glucokinase expression that is a key regulator of glucose metabolism in hepatocytes (Ling et al., 2016).

Conversely, nutrient conditions can influence the degree of PXR activity. PCN can amplify the expression of multiple well-known PXR target genes in glucose-fed mice compared with levels at the basal status (Hassani-Nezhad-Gashti et al., 2019). Hyperglycemia is a dangerous factor that induces diabetes, fatty liver disease, and cardiovascular disease. Therefore, it is an effective approach for the treatment of metabolic diseases by targeting hyperglycemia (Chen, Chen et al., 2019). Based on this, there is a need to develop novel therapeutic drugs that contrapuntally inhibit hepatic glucose production. The effect of PXR in the context of glucose metabolism is complex and may be influenced by the nutrient status, species, and other environmental factors. Key aims for future research targeting PXR include the development of drugs possessing tissue selectivity and clinical safety with a specific nutrient statement.

The Role of PXR in Cholesterol Metabolism

Cholesterol homeostasis is a vital substrate of the cell membrane and is vital for cell membrane maintenance and systemic function. Intracellular cholesterol metabolism is maintained by a complex network that regulates cholesterol biosynthesis, uptake, export, esterification, and trafficking (Xu et al., 2020) as presented in Fig. 1. Dysregulated cholesterol metabolism cannot only cause cardiovascular diseases but can also induce a large number of other metabolic diseases.




Fig. 1. Overview of whole-body cholesterol metabolism. Cholesterol metabolism is maintained by an array of regulatory processes controlling absorption, de novo synthesis, hepatic lipoprotein production, lipoprotein uptake, and efflux. The enterocytes are responsible for absorbing diet cholesterol and converting it into chylomicron, which is further transported to the blood. LDL uptake through LDL receptors and hydrolysis to cholesterol via lysosome. In liver cells, the biosynthesis pathway converts acetyl-CoA into cholesterol through nearly 30 enzymatic reactions, during which 3-hydroxy-3-methylglutaryl-CoA reductase and squalene epoxidase are the two key speed-limiting enzymes. Cholesterol can be converted to BA, oxysterols, or esterified to lipid droplets. Liver cells synthesize high-density lipoprotein and efflux via ATP-binding cassette transporter A1 and ATP-binding cassette transporters G1. ABCA1, ATP-binding cassette transporter A1; ABCG1, ATP-binding cassette transporters G1; ABCG5/G8, ATP-binding cassette transporters G5 and G8; ACAT2, acetyl CoA acetyltransferase 2; acetyl-CoA, acetyl coenzyme A; Farnesyl-PP, Farnesyl pyrophosphate; FDFT1, farnesyl-diphosphate farnesyltransferase 1; HMG-CoA, 3-hydroxy-3-methylglutaryl-CoA; HMGCR, HMG-CoA reductase; HMGCS, 3-hydroxy-3-methylglutaryl-CoA synthetase; LSS, lanosterol synthase; NPC1, NPC intracellular cholesterol transporter 1; NPC1L1, Niemann-Pick C1-like 1; SQLE, squalene epoxidase.

As an XR, PXR has been demonstrated to possess the effects to induce hypercholesterolemia and modulate the content of cholesterol. Treating wild-type mice with PXR agonists increased serum high-density lipoprotein cholesterol and apolipoprotein A1 levels (Bachmann et al., 2004). PXR activation diminishes plasma low-density lipoprotein (LDL) cholesterol levels and leads to hepatic steatosis in LDL-knockout mice (Hoekstra et al., 2009). A recent study revealed that dicyclohexyl phthalate is an underlying intestinal PXR-selective agonist that elevates plasma cholesterol levels in wild-type mice. Interestingly, dicyclohexyl phthalate exposure also led to higher circulating ceramide levels and increased the expression of intestinal genes mediating lipogenesis in a PXR-dependent manner, thus suggesting that intestinal PXR plays a vital role in cholesterol and lipid metabolism (Sui et al., 2021).

For the underlying mechanism, the cholesterol biosynthesis enzyme squalene epoxidase was confirmed as an immediate transcriptional target of PXR and caused the elevated cholesterol biosynthesis (Gwag et al., 2019). Salonurmi et al. (2020) determined that an agonist of the liver X receptor (LXR), circulating 4 β -hydroxycholesterol, is elevated by PXR activation. PXR activation induces cholesterol efflux and its transporters ABCA1 and ABCG1 while suppressing the influx of cholesterol and its transporter lectin-like oxidized LDL receptor-1. This is dependent upon elevated 4 β -hydroxycholesterol levels and further LXR activation. Rifampicin induces CYP27A1 gene transcription, increases intracellular 27-hydroxycholesterol levels, and induces ABCA1 and ABCG1 mRNA expression only in intestinal cells, and this stimulates

cholesterol efflux from intestinal cells to apolipoprotein A-I and high-density lipoprotein in the circulation (Li et al., 2007; Lin et al., 2018). Quetiapine, an antipsychotic medicine, has recently been determined to specifically activate intestinal PXR that further stimulates intestinal expression of the cholesterol transporter Niemann-Pick C1-like 1 and microsomal triglyceride transfer protein to thereby increase lipid absorption in intestinal (Meng et al., 2019). PXR activation elevates the atherogenic lipoproteins very low-density lipoprotein and LDL levels due to the decreased expression of CD36, ApoA-IV, and CYP39A1, all of which participate in cholesterol metabolism and lipoprotein transportation (Zhou et al., 2009). Interestingly, in apoE^{-/-} mice, deficiency in PXR did not change cholesterol levels in plasma but instead attenuated atherosclerosis development, and this may result from reduced CD36 expression and lowered CD36-mediated oxidized LDL uptake in peritoneal macrophages (Zhou et al., 2009; Sui et al., 2011). In human volunteers, PXR activation by rifampicin increased intermediate-density lipoprotein, LDL, total cholesterol, and the lathosterol-cholesterol ratio (a marker of cholesterol synthesis), thus suggesting elevated cholesterol synthesis. The elevated cholesterol levels were caused by widespread induction of cholesterol synthesis genes, including the rate-limiting Hmgcr, and by upregulation of the intermediates in the Kandutsch-Russell cholesterol synthesis pathway in the liver (Karpale et al., 2021). Additionally, the activation of PXR induces plasma proprotein convertase subtilisin/kexin type 9, which is an inhibitor of hepatic LDL uptake, and these roles are mediated by elevated proteolytic activation of SREBP2 in response to PXR activation (Karpale et al., 2021).

Through complex coordinated regulation, PXR regulates key aspects of cholesterol metabolism and participates in metabolic diseases, including cholesterol synthesis, remodeling, absorption, cholesterol uptake by peripheral tissues, and reverse cholesterol transport. However, in different tissues and specific pathologic environments, the effects of PXR may vary through different mechanisms. Certain clinical drugs exhibit the potential to activate PXR, and their clinical use should be considered due to their role in regulating cholesterol metabolism that may be a risk factor for hypercholesterolemia.

Roles of PXR in Bile Acid Metabolism

BAs are key agents that are responsible for intestinal nutrient absorption and the biliary secretion of toxic metabolites, lipids, and xenobiotics (Chiang, 2013). BAs are primarily synthesized from cholesterol in the liver via classic and alternative pathways and comprise a major part of cholesterol metabolism (Yang and Zhang, 2020; Wang et al., 2021). Cholesterol is converted to cholic acid and chenodeoxycholic acid, which are two major BAs in the liver. In rodents, chenodeoxycholic acid is further metabolized to α/β -muricholic acid. BAs are primarily conjugated with taurine and glycine, catalyzed by CYPs, secreted into the bile, and stored in the gallbladder. After a meal, BAs are secreted into the intestine and converted into secondary BAs by bacterial enzymes, including deoxycholic acid and LCA (Russell, 2003; Wang, Wang et al., 2018).

In enterohepatic circulation, BAs are secreted from the liver to the intestine and then back to the liver, dependent on their micelle-forming properties. These physiologic functions play a key role in nutrient absorption and distribution, metabolic regulation, and homeostasis (Ahmad and Haeusler, 2019). BAs are being increasingly investigated as complex metabolic integrators and signaling factors—not just as lipid solubilizers but also as simple modulators of BA homeostasis (Thomas et al., 2008). Disruption of BA metabolism can cause cholestatic liver disease, diabetes, dyslipidemia, and cardiovascular diseases (Li and Chiang, 2014). Previous studies have suggested that BAs primarily activate the farnesoid X receptor and Takeda G protein-coupled receptor 5 to modulate lipid and glucose metabolic homeostasis and energy metabolism in the liver, gut, and peripheral tissues. However, certain investigations have confirmed that PXR also participates in BA metabolism and influences metabolic diseases (Chávez-Talavera et al., 2017; Chiang and Ferrell, 2018; Castellanos-Jankiewicz et al., 2021).

A 4-day treatment with a high dose of DEX (75 mg/kg) has been used in assorted investigations to activate PXR signaling in mice (Klaassen and Aleksunes, 2010). A recent study revealed that 75 mg/kg of DEX did not alter the total BA concentrations in mice serum but significantly decreased the total unconjugated BAs and total secondary BAs in the liver, thus suggesting the beneficial effects of PXR activation on cholestasis by reducing BA concentrations in the liver (Wang, Wang et al., 2018). The role of PXR activation was mediated by increased levels of fibroblast growth factor-19, a key modulator in inhibiting hepatic BA synthesis, as confirmed by another study (Guthrie et al., 2020). Analysis of specific components of BAs in serum revealed that PXR activation by 75 mg/kg DEX treatment elevated taurocholate and taumuricholate content and decreased deoxycholic acid and taumuricholic acid in the serum, thus suggesting that PXR activation may exert an inhibitive effect on intestinal bacteria that synthesis secondary BAs (Wang, Wang et al., 2018). Further studies have confirmed that PXR activation induced by PCN downregulates BA-metabolizing bacteria in the intestine and regulates BA homeostasis in a gut microbiota-dependent manner (Dempsey et al., 2019). Besides regulating intestinal bacteria and secreted factors, PXR can regulate BAs by modulating the expression of its synthetic enzymes, including the key enzymes cholesterol 7 α -hydroxylase and sterol 12 α -hydroxylase, in the classic BA synthesis

pathway (Zhao et al., 2017). Besides, as BAs synthetic enzymes, PXR regulates BAs oxidation and conjugation by controlling the expression of GST, UGT, and SULT. Moreover, PXR modulates the expression of genes responsible for BAs secretion including ABC and OATP membrane transporters (Modica et al., 2009).

As one of the key ligands of PXR, BAs can regulate PXR activity. The severity of BA malabsorption is closely related to PXR deactivation. Enterohepatic circulation of BAs is a key factor for preserving baseline hepato-intestinal PXR activity (Iwamoto et al., 2013). BAs are also determined to be a major factor in the cross-talk mediated by PXR and activated CYPs (Hafner et al., 2011). PXR responds to secondary BAs and induces their catabolism (Makishima, 2005). These findings illustrate a feed-forward regulatory pathway between BAs and PXR, where BAs can regulate PXR activity and induce their own metabolism.

The Role of PXR in Innate Immunity

Metabolic diseases are often accompanied by systemic inflammations. It is also widely recognized that chronic inflammation plays a critical role in the initiation and progression of metabolic diseases (Baker et al., 2011). It has long been confirmed that exposure to xenobiotics and PXR activation can impair the immune system. Recently, a large number of investigations have demonstrated the modulatory effects and underlying mechanisms of PXR on inflammation.

PXR mitigates inflammatory injury through the negative regulation of inflammatory pathways and cytokines such as nuclear factor kappa B (NF- κ B), Toll-like receptor 4 (TLR4), signal transducer and activator of transcription 3, IL-6, tumor necrosis factor α , and other pathways.

St. John's wort, a PXR agonist, can activate PXR and further inhibit tumor necrosis factor α -induced NF- κ B translocation and activation (Yan et al., 2021). Intestinal PXR activation exerts a protective effect in the context of inflammatory bowel disease, and this is partially due to the attenuation of NF- κ B signaling that leads to lower expression of cytokines (Cheng et al., 2012). Furthermore, PXR directly interacts with NF- κ B and activator protein 1 to decrease inflammation-induced expression of chemokine CXCL2 and suppress neutrophil infiltration in the liver (Okamura et al., 2020). Further studies suggested that the anti-inflammatory effect of PXR was mediated by the inhibition of NF- κ B activity by enhancing nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (I κ B α ; a suppressor of NF- κ B) expression in tetrachloromethane (CCl₄)-induced mouse liver inflammation. PXR/retinoid X receptor α binds to two sites in the upstream regulation of I κ B α and enhances I κ B α expression in a dose-dependent way (Ye et al., 2016).

PXR has also been confirmed to negatively regulate TLR4 signaling (Huang et al., 2018). PXR activation reduces TLR4 expression by decreasing TLR4 mRNA stability (Huang et al., 2018). PXR regulates pathogen-induced inflammation and host defense against viral infection by regulating the TLR4 signaling (Qiu et al., 2016). The effects of PXR activation on TLR4 signaling have been reported mostly in intestinal diseases. The intestinal microbial metabolite indole 3-propionic acid, a ligand for PXR in vivo, modulates mucosal integrity and inflammation via a pathway that involves luminal sensing and signaling by TLR4 (Venkatesh et al., 2014). Rifaximin improved *Clostridium difficile* toxin-induced intestinal epithelial cell apoptosis and inflammation via the PXR-dependent TLR4/MyD88/NF- κ B pathway and may be effective in *Clostridium difficile* infections treatment (Esposito et al., 2016). Following intrarectal exposure to TcdA/B, PXR-deficient mice (Nr1i2^{-/-}0076) exhibited reduced survival, and this effect was related to elevated levels of innate immune cell influx. This exacerbated response was abolished by TLR4 signaling blocking (Erickson et al., 2020). Regarding the underlying mechanism, a study reported that patchouli alcohol increased

the expression of the nuclear receptor PXR and promoted the PXR/TLR4 axis to suppress the nuclear import of NF- κ B (p50 and p65) during osteoporosis (Lu et al., 2021). IL-35-producing Bregs and Treg cells critically modulate chronic illnesses worldwide through mechanisms related to the disruption of gut microbiota composition. Treatment with 3-iodoleacetic acid together with lipopolysaccharide (LPS) induces IL-35 + B cell generation through PXR and TLR4 (Su et al., 2022). These findings reveal a negative regulatory effect of PXR on TLR4 signaling during intestinal disease. However, the underlying mechanisms by which PXR regulates TLR4 in the context of metabolic diseases must be clarified.

PXR can modulate liver inflammation by regulating the inflammation-prone gut microbiome signature that differs between males and females. PXR knockout mice exhibit downregulation of hepatic genes involved in microbial responses and inflammation. This was due to the decrease in proinflammatory *Lactobacillus* and the elevation in anti-inflammatory *Bifidobacterium* in a PXR-dependent manner in the intestine (Kim, Choi et al., 2021).

Conversely, the inflammatory response can modulate the expression of PXR and its downstream target genes. During LPS-induced liver inflammation, LPS largely inhibited PXR expression in a dose-dependent way, and this was followed by the inhibition of CYP3A11 in the mouse liver (Xu et al., 2004). A further mechanistic study suggested that Kupffer cells and reactive oxygen species that are possibly produced by nicotinamide adenine dinucleotide phosphate oxidase and xanthine oxidase are involved in LPS-induced downregulation of nuclear receptor PXR and its target gene CYP3A in the mouse liver (Xu et al., 2004). NF- κ B-mediated inflammation can influence PXR phosphorylation and activation. NF- κ B directly regulates PXR signaling via interacting with its dimerization partner retinoid X receptor α (Bautista-Olivier and Elizondo, 2022). The inflammatory cytokine IL-6 can suppress PXR expression, and this is mediated by the NF- κ B pathway (Li, Lan et al., 2021). The regulatory effect of PXR during inflammation suggests that PXR is an anti-inflammatory modulator of inflammatory bowel disease and toxin-induced liver injury. Inflammation plays a complex role in metabolic diseases. In the initial stages of NAFLD, inflammation is responsible for the repair and defense of external substances. However, an inflammatory response promotes NAFLD progression after persistent external stimulation. The anti-inflammatory effects of PXR in the treatment of metabolic diseases such as NAFLD should consider the specific stage of these metabolic diseases.

PXR also exerts nongenomic and antithrombotic effects during atherosclerosis. PXR is expressed in human platelets. Treatment with PXR ligands inhibited platelet functions stimulated by a range of agonists with platelet aggregation, granule secretion, adhesion, and spreading on fibrinogen, all of which were attenuated along with a reduction in thrombus formation (both in vitro and in vivo). The PXR ligand-mediated inhibition of platelet function was determined to be related to the depression of Src family kinases (Flora et al., 2019).

PXR may participate in the metabolism of multiple nutrients, and its role in metabolic diseases is complex. Nutrient metabolism is a sophisticated metabolic network that often intertwines and regulates itself (Ahmad and Haeusler, 2019). PXR knockout alleviates HFD-induced obesity by inducing FGF15 expression, thus leading to the inhibition of BA synthesis and the reduction of lipid absorption, hepatic lipid accumulation, and liver triglyceride levels (Zhao et al., 2017). Statins are therapeutic drugs that modulate serum cholesterol levels and decrease the risk of heart disease. They are confirmed to change the microbial composition, alter BA components, and increase fasting blood glucose levels and body weight through a PXR-dependent mechanism (Caparrós-Martín et al., 2017). The wide distribution of PXR in the body causes difficulties in specific metabolic diseases treatment. Concurrently, PXR in different

tissues and specific pathologic environments may exert different effects on disease, thus indicating its complex functions. Future investigations should focus on investigating the role and mechanism of PXR in the context of metabolic diseases in various pathologic environments.

CAR in Metabolic Disease

In addition to acting as an XR, the activation of CAR alleviates insulin resistance, represses lipogenesis and gluconeogenesis, and upregulates brown adipose tissue energy expenditure during metabolic diseases (Yan et al., 2015). CAR shares some common downstream target genes with PXR but can also modulate lipid, glucose, cholesterol, and BA metabolism in specific pathways.

CAR in Lipid Metabolism

Previous studies have suggested that activation of CAR results in decreased hepatic triglyceride levels (Yan et al., 2015). CAR activation downregulates liver lipid deposition and lipogenic gene (Srebp1c, Fasn, and Scd-1) expression in ob/ob mice, and this is dependent upon sulfotransferase 2B1b induction (Dong et al., 2009). The activation of CAR by TCPOBOP also induced lipid β -oxidation in the liver (Dong et al., 2009). A mouse-specific CAR ligand, TCPOBOP, can reduce liver and plasma triglyceride levels. However, TCPOBOP regulated lipid homeostasis by increasing serum and liver triglyceride levels and promoting hepatocyte hypertrophy in humanized CAR mice without human CAR activation. This suggests that the roles of TCPOBOP on lipid metabolism are independent of human CAR activation (Skoda et al., 2022). LXRs (NR1H2/3) function as cholesterol sensors, thus protecting mammals from cholesterol overload. Specifically, CAR loss elevated lipogenic LXR target genes expression, ultimately resulting in elevated hepatic triglyceride accumulation (Xiao et al., 2010). CAR activation in the mouse liver leads to insulin-induced gene-1 activation (an antilipogenic protein) and with a reduction in the active form of Srebp-1 levels (Roth et al., 2008). In the liver, CAR competitively binds to the DR1 motif and to GRIP-1 and PGC-1 α that are common coactivators to inhibit HNF-4 activity. This may be a general underlying mechanism by which CAR downregulates key genes involved in hepatic lipid and glucose metabolism (Miao et al., 2006). Treatment of mice with phenobarbital, another CAR activator, suppresses the interaction between PPAR α and PGC1 α in the liver, thus attenuating PPAR α -dependent lipid metabolism (Shizu et al., 2020). However, phenobarbital significantly elevated plasma triglyceride levels in contrast to the action of TCPOBOP (Skoda et al., 2022). Interestingly, Marmugi et al. (2016) reported that CAR activation induced hepatic lipogenesis and regulated patatin-like phospholipase domain-containing protein 3 expression in an LXR-independent pathway to promote NAFLD. CAR downregulated liver lipid metabolism through the LXR-Srebp1 pathway and its downstream target genes, such as sulfotransferase 2B1b, insulin-induced gene-1, and hepatocyte nuclear factor 4 α . Interestingly, there is a series of reports regarding the effects of CAR on lipid metabolism. CAR activation by TCPOBOP induces hepatic lipogenesis and promotes NAFLD progression. In humanized CAR mice, TCPOBOP increased triglyceride levels serum and liver. In hyperlipidemic mice, TCPOBOP treatment significantly reduced plasma triglyceride and intermediate-density lipoprotein/LDL cholesterol levels and very low-density lipoprotein production in the liver and was accompanied by a decrease in hepatic triglyceride content and the repression of several genes involved in lipogenesis (Sberna, Assem, Xiao et al., 2011). TCPOBOP and phenobarbital exhibited the opposite effects in regard to the regulation of plasma triglyceride levels. These investigations revealed that the modulation of lipid metabolism by CAR is more complex than we initially assumed and depends on the metabolic context. Different types of CAR ligand

treatments may regulate lipid metabolism not only through CAR activation, and further investigation of the underlying mechanism is required in regard to their application in metabolic diseases.

CAR in Glucose Metabolism

CAR activation not only tightly modulates lipid metabolism but also influences hepatic glucose metabolism. In diabetic mice, CAR activation significantly decreases serum glucose levels and improves glucose tolerance by inhibiting glucose production and stimulating glucose uptake. The decreased glucose production by CAR activation was caused by interfering with forkhead box protein O1 and influencing hepatocyte nuclear factor 4 α activity to downregulate PEPCK and G6pase expression (Kodama et al., 2004; Miao et al., 2006; Kachaylo et al., 2012). CAR stimulates glucose uptake via increasing hexokinase and phosphogluconate dehydrogenase activities that are enzymes responsible for the first irreversible step in glycolysis and a rate-limiting enzyme in the pentose phosphate pathway, respectively (Dong et al., 2009; Chen, Coslo et al., 2019). Lynch et al. (2014) reported an important species difference between human CAR and mouse CAR in terms of hepatic energy metabolism. Activation of mouse CAR inhibits genes related to gluconeogenesis, FA synthesis, and lipogenesis. However, human CAR activation especially depresses gluconeogenesis by decreasing G6pase and PEPCK expression without interfering with FA synthesis. Liver tissue metabolome analysis also demonstrated that CAR activation significantly decreased the components involved in key gluconeogenic pathways and increased the content contributing to glucose utilization pathways. These changes were due to the downregulation of the hepatic glucose sensor and the bidirectional transporter Glut2 (Chen, Coslo et al., 2019).

CAR in Cholesterol and Bile Acid Metabolism

CAR also plays a vital role in cholesterol and BA metabolism. CAR can elevate BA content and decrease hepatic cholesterol levels by regulating downstream target gene expression. Sberna, Assem, Gautier et al. (2011) determined that long-term CAR activation is related to decreased whole-body cholesterol content and atherosclerosis susceptibility. For the underlying mechanism, CAR activation suppressed *Abcg5* and *Abcg8* expression and consequently lowered the biliary cholesterol level. In the same study, CAR activation promoted the conversion of cholesterol to BAs via elevating the expression of *CYP7a1*, a rate-limiting enzyme in BA synthesis. CAR activation enhances BA reabsorption by enhancing the expression of the BA transporters *Abst* and *Ost β* , and this further alleviates cholesterol gallstone disease (Cheng et al., 2017). In addition to regulating the enzymes responsible for BA metabolism and transport, CAR can cross-talk with PXR by either competing for common coactivators or by disrupting the coactivation of other transcription factors (Pavek, 2016).

Bilirubin, LCA, and steroids can indirectly enhance CAR transcriptional activity in BA metabolism. Downstream target gene encoding for enzymes of CAR are participated in the oxidative metabolism (CYPs), conjugation (GSTs, UGTs, and SULTs), and transport (ABCs and OATPs) of BAs (Modica et al., 2009). In summary, CAR acts in concert to establish a metabolic safety network against BA by inhibiting its synthesis and inducing the genes responsible for phase I (hydroxylation), phase II (conjugation), and phase III (excretion) metabolism. Indeed, by binding and activating CAR, BAs stimulate CAR in a feed-forward manner, thus regulating the expression of BA enzymes and membrane transporters that are responsible for BA clearance.

AHR in Metabolic Disease

AHR is an evolutionarily conserved sensor that integrates environmental, microbial, metabolic, and endogenous signals into specific cellular responses. It is associated with autoimmune, neoplastic, metabolic, and degenerative diseases (Rothhammer and Quintana, 2019). Therefore, the study of AHR regulation and function may direct the development of novel therapeutic interventions for these diseases.

The Functional Role of AHR in Inflammation During Metabolic Disease

As a cytoplasmic receptor and transcription factor, AHR has been previously speculated to play a key role in immunity and tissue homeostasis (Shinde and McGaha, 2018). AHR regulates adaptive immunity by inducing Th17 cells, stabilizing Treg and Tr1 cells, and priming anti-inflammatory dendritic cells (Rothhammer and Quintana, 2019).

During metabolic diseases, intestinal AHR plays a dominant role in regulating inflammation, and this further alleviates disease progression. In patients with obesity and type 2 diabetes, elevated plasma IL-22 and IL-17 levels were accompanied by increased AHR transcripts in peripheral blood mononuclear cells, thus suggesting that AHR may play a plausible role in the interaction between proinflammatory status and metabolism in type 2 diabetes and obesity (Zhao et al., 2020). In an HFD mouse model, AHR activation elicited IL-22 production in the gut that improved intestinal barrier permeability and decreased endotoxemia (Lin et al., 2019). AHR activation defended chemically induced damage to intestinal barrier integrity and decreased inflammatory cytokine expression in intestinal cells through the p38-MAPK pathway, thus further alleviating obesity (Postal et al., 2020). Myeloid cell AHR nuclear translocator knockout promoted the conversion from NAFLD to steatohepatitis with increased hepatic macrophage infiltration and M1 macrophage marker expression (Scott et al., 2019). The studies suggest that the protective role of AHR in inflammation during metabolic diseases is different from its role in adaptive immunity.

The Functional Role of AHR in Metabolic Disease

In patients with obesity, serum AHR levels were determined to be significantly higher, and this is correlated with food consumption, thus suggesting a vital important role of AHR in obesity (Andac-Ozturk et al., 2021). In AHR whole-body knockout mice, adiposity was increased and was accompanied by decreased glucose tolerance. Liver steatosis was also accelerated with increased hepatic triglyceride accumulation and decreased blood lipids (Jin et al., 2021). Treatment with an AHR agonist alleviates insulin resistance and serum and liver triglyceride content in diabetic mice (Natividad et al., 2018). A recent study reported that saccharin/sucralose remarkably inhibited microbiota-derived AHR ligands and AHR expression in colon, and this further elevated serum and hepatic FA levels, ultimately causing NAFLD in mice (Shi et al., 2021). Tissue-specific AHR deficiency in mature adipocytes through adiponectin-Cre promotes obesity, whereas hepatic AHR deficiency exacerbates steatosis without exerting significant effects on obesity, thus suggesting a different role for AHR in specific tissues (Gourronc et al., 2020). For the underlying mechanism, decreased microbiota production of AHR ligands leads to AHR inactivation, and this causes defective mucosal barrier integrity, reduced glucagon-like peptide 1 secretion, and the development of more severe metabolic syndrome (Natividad et al., 2018). AHR can also influence metabolic diseases by regulating inflammation. Lin et al. (2019) identified an AHR ligand agonist, indigo, as a promoter of IL-10 and IL-22 that defends from HFD-induced insulin resistance and fatty liver disease in a diet-induced obesity model. These effects are mechanistically related to downregulated inflammatory immune cell tone in tissues. Interestingly,

Xu et al. (2015) reported different results. AHR knockout protected against HFD-induced hepatic steatosis, insulin resistance, obesity, and inflammation resulting from higher energy expenditure accompanied by elevated mitochondrial β -oxidation gene expression and thermogenic gene uncoupling protein 1. In NAFLD, AHR activation can promote the expression of the estrogen metabolic enzyme CYP1A1, which is critical in the estrogen pathway, thus resulting in the inhibition of FA oxidation, suppression of hepatic export of triglycerides, and an elevation in peripheral fat mobilization (Zhu et al., 2020). Further studies have revealed that an activated AHR is necessary but not sufficient to attain obesity, a status that mostly obtains fat from the diet, thus suggesting that the modulatory role of AHR is dependent upon the nutrient environment (Rojas et al., 2021).

Overall, AHR was confirmed to regulate metabolic diseases, and this was primarily due to its modulation of intestinal integrity, anti-inflammatory effects, and downstream target gene expression. However, the underlying mechanisms of AHR regulation of lipids, glucose, cholesterol, and BAs remain poorly understood, and the effects of AHR on metabolic diseases in different physiologic states remain controversial. More studies are required to investigate the regulatory roles of AHR on specific metabolic components in different physiologic states, as this may expand the knowledge of AHR in the context of metabolic diseases.

Discussion

In this review, we highlight the regulatory effect of three XRs (PXR, CAR, and AHR) in lipid, glucose, cholesterol, and BA metabolism during metabolic diseases. Considering the increased prevalence of metabolic diseases and the growing concerns regarding human exposure to xenobiotics in the environment, knowledge of XRs and the regulation of metabolic diseases is important (Gulliver, 2017).

XR is a vital regulator of metabolic diseases. However, a number of ligands of XRs exert diverse effects in humans and rodents. Therefore, the confirmation of endogenous ligands, particularly those with species specificity, will expand our knowledge of the biology of XRs in different species. Concurrently, XRs share some common ligands and downstream target genes, thus further regulating metabolic diseases. XRs in different tissues and specific pathologic environments may exert different effects on diseases, thus indicating their complex functions. Although PXR activation may promote hepatic FA deposition and lipogenesis and lead to steatosis, its immunosuppressive effects on the intestine and immune cells may be beneficial for metabolic disorders by alleviating chronic inflammation (Gao and Xie, 2012). Investigations examining selective XRs regulators may provide new therapeutic tools for metabolic disorder management. Furthermore, identifying novel downstream target genes during the regulation of XRs in metabolic diseases and exploring the treatment of metabolic diseases may be more effective.

XR can be activated by a series of xenobiotics and can stimulate downstream target genes expression, including phase I and II enzymes and drug transporters. Most drugs and xenobiotics are metabolized in the liver. Among others, different CYP enzymes catalyze the metabolic conversion of foreign compounds, and various transport proteins are involved in the excretion of metabolites from hepatocytes (Hammer et al., 2021). The expression and activity of drug-metabolizing enzymes and transporters plays a decisive role in determining the pharmacokinetic properties of a compound in a given test system. Therefore, XRs are implicated in multiple drug-drug interactions that can lead to alterations in drug pharmacokinetics and cause fluctuating therapeutic efficacies. Among all of the downstream target genes, CYP3A4 is the primary isoform of CYP oxidases participated in the metabolism of approximately

60% drugs, and its expression level is highly variable in human subjects (Du et al., 2013). CYP3A4 induction can result in serious toxicological consequences as a result of elevated drug metabolism that contributes to drug-drug interactions, the bioactivation of xenobiotics to carcinogenic or toxic metabolites, and possibly endocrine disruption (Chai et al., 2013). Besides CYPs, several other phase I enzymes also play notable roles in the clearance of drugs by hydrolysis, reduction, and oxidation. PCN could significantly influence the pharmacokinetics of ursolic acid in rats, and it exhibited discrepant effects on the messenger RNA expression of CYP and transporters in tissues (Jinhua et al., 2020). Moreover, PCN significantly elevated Oatp2 expression and influenced the pharmacokinetics of sorafenib. Microvascular density and vascular endothelial growth factor levels in tumor-adjacent tissues declined significantly, thus suggesting that elevated Oatp2 expression enhances the therapeutic effect of sorafenib in a rat model of liver cancer (Wen and Zhao, 2021). Other factors also affect drug pharmacokinetics through PXR. Interferon- α has been suggested to cause pharmacokinetic drug interactions by decreasing the expression of drug disposition genes by influencing NF- κ B and PXR activities (Theile et al., 2021). Besides PXR, CAR can influence drug pharmacokinetics through the regulation of CYP1A, UGTs, and SULTs (Fu et al., 2020). A series of approved drugs such as imiquimod were confirmed to be metabolized by AHR-regulated CYP enzymes in vivo and in vitro (Mescher et al., 2019; Shimizu et al., 2021).

Considering the properties of XRs, it is recommended that researchers and clinicians consider their effects on drug metabolism when designing XRs as therapeutic targets for metabolic diseases. Concurrently, owing to the functions of XRs, agonists or antagonists of these receptors may possess therapeutic potential in regard to the correct management of certain diseases.

Authorship contributions

Wrote or contributed to the writing of the manuscript: Zhang, Jia, Li, He.

References

- Ahmad TR and Haeusler RA (2019) Bile acids in glucose metabolism and insulin signalling: mechanisms and research needs. *Nat Rev Endocrinol* **15**:701–712.
- Alves-Bezerra M and Cohen DE (2017) Triglyceride metabolism in the liver. *Compr Physiol* **8**:1–8.
- Andac-Ozturk S, Koc G, and Soyocak A (2021) Association of aryl hydrocarbon receptor (AhR) serum level and gene rs10247158 polymorphism with anthropometric, biochemical parameters and food consumption in overweight/obese patients. *Int J Clin Pract* **75**:e14436.
- Bachmann K, Patel H, Batayneh Z, Slama J, White D, Posey J, Ekins S, Gold D, and Sambucetti L (2004) PXR and the regulation of apoA1 and HDL-cholesterol in rodents. *Pharmacol Res* **50**:237–246.
- Bae SDW, Nguyen R, Qiao L, and George J (2021) Role of the constitutive androstane receptor (CAR) in human liver cancer. *Biochim Biophys Acta Rev Cancer* **1875**:188516.
- Baker RG, Hayden MS, and Ghosh S (2011) NF- κ B, inflammation, and metabolic disease. *Cell Metab* **13**:11–22.
- Bautista-Olivier CD and Elizondo G (2022) PXR as the tipping point between innate immune response, microbial infections, and drug metabolism. *Biochem Pharmacol* **202**:115147.
- Bhalla S, Ozalp C, Fang S, Xiang L, and Kemper JK (2004) Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1 α . Functional implications in hepatic cholesterol and glucose metabolism. *J Biol Chem* **279**:45139–45147.
- Bhushan B, Molina L, Koral K, Stroops JW, Mars WM, Banerjee S, Orr A, Paranjpe S, Monga SP, Locker J, et al. (2021) Yes-associated protein is crucial for constitutive androstane receptor-driven hepatocyte proliferation but not for induction of drug metabolism genes in mice. *Hepatology* **73**:2005–2022.
- Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, and Armstrong A (2021) Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. *J Am Acad Dermatol* **84**:1059–1067.
- Biswas A, Pasquel D, Tyagi RK, and Mani S (2011) Acetylation of pregnane X receptor protein determines selective function independent of ligand activation. *Biochem Biophys Res Commun* **406**:371–376.
- Bitter A, Rümmele P, Klein K, Kandel BA, Rieger JK, Nüssler AK, Zanger UM, Trauner M, Schwab M, and Burk O (2015) Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. *Arch Toxicol* **89**:2089–2103.
- Bódis K and Roden M (2018) Energy metabolism of white adipose tissue and insulin resistance in humans. *Eur J Clin Invest* **48**:e13017.
- Brewer CT and Chen T (2016) PXR variants: the impact on drug metabolism and therapeutic responses. *Acta Pharm Sin B* **6**:441–449.
- Cai X, Young GM, and Xie W (2021) The xenobiotic receptors PXR and CAR in liver physiology, an update. *Biochim Biophys Acta Mol Basis Dis* **1867**:166101.

- Caparrós-Martín JA, Lareu RR, Ramsay JP, Peplies J, Reen FJ, Headlam HA, Ward NC, Croft KD, Newsholme P, Hughes JD, et al. (2017) Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism. *Microbiome* **5**:95.
- Carazo A, Mladenka P, and Pávek P (2019) Marine ligands of the pregnane X receptor (PXR): an overview. *Mar Drugs* **17**:E554.
- Castellanos-Jankiewicz A, Guzmán-Quevedo O, Fénelon VS, Zizzari P, Quarta C, Bellocchio L, Tailleux A, Charton J, Férandois D, Henriksen M, et al. (2021) Hypothalamic bile acid-TGR5 signaling protects from obesity. *Cell Metab* **33**:1483–1492.e10.
- Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, Ulrichova J, Anzenbacher P, and Pavek P (2007) Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. *Drug Metab Dispos* **35**:1032–1041.
- Chai SC, Cherian MT, Wang YM, and Chen T (2016) Small-molecule modulators of PXR and CAR. *Biochim Biophys Acta* **1859**:1141–1154.
- Chai X, Zeng S, and Xie W (2013) Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond. *Expert Opin Drug Metab Toxicol* **9**:253–266.
- Chávez-Talavera O, Tailleux A, Lefebvre P, and Staels B (2017) Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. *Gastroenterology* **152**:1679–1694.e1673.
- Chen F, Coslo DM, Chen T, Zhang L, Tian Y, Smith PB, Patterson AD, and Omiecinski CJ (2019) Metabolomic approaches reveal the role of CAR in energy metabolism. *J Proteome Res* **18**:239–251.
- Chen L, Chen XW, Huang X, Song BL, Wang Y, and Wang Y (2019) Regulation of glucose and lipid metabolism in health and disease. *Sci China Life Sci* **62**:1420–1458.
- Chen T, Laurenzana EM, Coslo DM, Chen F, and Omiecinski CJ (2014) Proteasomal interaction as a critical activity modulator of the human constitutive androstane receptor. *Biochem J* **458**:95–107.
- Cheng J, Shah YM, and Gonzalez FJ (2012) Pregnane X receptor as a target for treatment of inflammatory bowel disorders. *Trends Pharmacol Sci* **33**:323–330.
- Cheng S, Zou M, Liu Q, Kuang J, Shen J, Pu S, Chen L, Li H, Wu T, Li R, et al. (2017) Activation of constitutive androstane receptor prevents cholesterol gallstone formation. *Am J Pathol* **187**:808–818.
- Cherian MT, Chai SC, and Chen T (2015) Small-molecule modulators of the constitutive androstane receptor. *Expert Opin Drug Metab Toxicol* **11**:1099–1114.
- Chiang JY (2013) Bile acid metabolism and signaling. *Compr Physiol* **3**:1191–1212.
- Chiang JYL and Ferrell JM (2018) Bile acid metabolism in liver pathobiology. *Gene Expr* **18**:71–87.
- Chouchani ET and Kajimura S (2019) Metabolic adaptation and maladaptation in adipose tissue. *Nat Metab* **1**:189–200.
- Cui W, Shen X, Agbas E, Tompkins B, Cameron-Carter H, and Staudinger JL (2020) Phosphorylation modulates the coregulatory protein exchange of the nuclear receptor pregnane X receptor. *J Pharmacol Exp Ther* **373**:370–380.
- Cui W, Sun M, Galeva N, Williams TD, Azuma Y, and Staudinger JL (2015) SUMOylation and ubiquitylation circuitry controls pregnane x receptor biology in hepatocytes. *Drug Metab Dispos* **43**:1316–1325.
- Daujat-Chavanieu M and Gerbal-Chaloin S (2020) Regulation of CAR and PXR expression in health and disease. *Cells* **9**:E2395.
- Dempsey JL, Wang D, Siginir G, Fei Q, Raftery D, Gu H, and Yue Cui J (2019) Pharmacological activation of PXR and CAR downregulates distinct bile acid-metabolizing intestinal bacteria and alters bile acid homeostasis. *Toxicol Sci* **168**:40–60.
- di Masi A, De Marinis E, Ascenzi P, and Marino M (2009) Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. *Mol Aspects Med* **30**:297–343.
- Di Tommaso N, Gasbarrini A, and Ponziani FR (2021) Intestinal barrier in human health and disease. *Int J Environ Res Public Health* **18**:12836.
- Dong B, Saha PK, Huang W, Chen W, Abu-Elheiga LA, Wakil SJ, Stevens RD, Ilkayeva O, Newgard CB, Chan L, et al. (2009) Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. *Proc Natl Acad Sci USA* **106**:18831–18836.
- Du QQ, Wang ZJ, He L, Jiang XH, and Wang L (2013) PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers. *Eur J Clin Pharmacol* **69**:1917–1925.
- Eckel RH, Grundy SM, and Zimmet PZ (2005) The metabolic syndrome. *Lancet* **365**:1415–1428.
- Erickson SL, Alston L, Nieves K, Chang TKH, Mani S, Flannigan KL, and Hirota SA (2020) The xenobiotic sensing pregnane X receptor regulates tissue damage and inflammation triggered by C difficile toxins. *FASEB J* **34**:2198–2212.
- Esposito G, Nobile N, Gigli S, Seguela L, Pesce M, d'Alessandro A, Bruzzese E, Capoccia E, Steardo L, Cuomo R, et al. (2016) Rifaximin improves clostridium difficile toxin a-induced toxicity in Caco-2 cells by the PXR-dependent TLR4/MyD88/NF- κ B pathway. *Front Pharmacol* **7**:120.
- Fiorucci S, Zampella A, and Distrutti E (2012) Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders. *Curr Top Med Chem* **12**:605–624.
- Fisher CD, Augustine LM, Maher JM, Nelson DM, Slitt AL, Klaassen CD, Lehman-McKeeman LD, and Cherrington NJ (2007) Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. *Drug Metab Dispos* **35**:995–1000.
- Flora GD, Sahli KA, Sasikumar P, Holbrook LM, Stainer AR, AlOuda SK, Crescente M, Sage T, Unsworth AJ, and Gibbins JM (2019) Non-genomic effects of the Pregnane X Receptor negatively regulate platelet functions, thrombosis and haemostasis. *Sci Rep* **9**:17210.
- Fu L, Zhou L, Geng S, Li M, Lu W, Lu Y, Feng Z, and Zhou X (2020) Catalpol coordinately regulates phase I and II detoxification enzymes of Triptolide through CAR and NRF2 pathways to reduce Triptolide-induced hepatotoxicity. *Biomed Pharmacother* **129**:110379.
- Furue M, Hashimoto-Hachiya A, and Tsuji G (2019) Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. *Int J Mol Sci* **20**:E5424.
- Gao J and Xie W (2012) Targeting xenobiotic receptors PXR and CAR for metabolic diseases. *Trends Pharmacol Sci* **33**:552–558.
- Gao Y, Fan S, Li H, Jiang Y, Yao X, Zhu S, Yang X, Wang R, Tian J, Gonzalez FJ, et al. (2021) Constitutive androstane receptor induced-hepatomegaly and liver regeneration is partially via yes-associated protein activation. *Acta Pharm Sin B* **11**:727–737.
- Geng Y, Faber KN, de Meijer VE, Blokzijl H, and Moshage H (2021) How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? *Hepatol Int* **15**:21–35.
- Goettel M, Fegert I, Honarvar N, Vardy A, Haines C, Chatham LR, and Lake BG (2020) Comparative studies on the effects of sodium phenobarbital and two other constitutive androstane receptor (CAR) activators on induction of cytochrome P450 enzymes and replicative DNA synthesis in cultured hepatocytes from wild type and CAR knockout rats. *Toxicology* **433–434**:152394.
- Gotoh S, Miyauchi Y, Moore R, and Negishi M (2017) Glucose elicits serine/threonine kinase VRK1 to phosphorylate nuclear pregnane X receptor as a novel hepatic gluconeogenic signal. *Cell Signal* **40**:200–209.
- Gouron FA, Markan KR, Kulhankova K, Zhu Z, Sheehy R, Quelle DE, Zingman LV, Kurago ZB, Ankrum JA, and Klingelutz AJ (2020) Pdgfr α -Cre mediated knockout of the aryl hydrocarbon receptor protects mice from high-fat diet induced obesity and hepatic steatosis. *PLoS One* **15**:e0236741.
- Goya-Jorge E, Rampil C, Loones N, Barigye SJ, Carpio LE, Gozalbes R, Ferroud C, Sylla-Iyarreta Veitia M, and Giner RM (2020) Targeting the aryl hydrocarbon receptor with a novel set of triarylmetanes. *Eur J Med Chem* **207**:112777.
- Gulliver LS (2017) Xenobiotics and the glucocorticoid receptor. *Toxicol Appl Pharmacol* **319**:69–79.
- Guthrie G, Stoll B, Chacko S, Lauridsen C, Plat J, and Burrin D (2020) Rifampicin, not vitamin E, suppresses parenteral nutrition-associated liver disease development through the pregnane X receptor pathway in piglets. *Am J Physiol Gastrointest Liver Physiol* **318**:G41–G52.
- Gwag T, Meng Z, Sui Y, Helsley RN, Park SH, Wang S, Greenberg RN, and Zhou C (2019) Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis. *J Hepatol* **70**:930–940.
- Hafner M, Rezen T, and Rozman D (2011) Regulation of hepatic cytochromes p450 by lipids and cholesterol. *Curr Drug Metab* **12**:173–185.
- Hammer H, Schmidt F, Marx-Stoelting P, Pötz O, and Braeuning A (2021) Cross-species analysis of hepatic cytochrome P450 and transport protein expression. *Arch Toxicol* **95**:117–133.
- Hassani-Nezhad-Gashti F, Kummu O, Karpale M, Rysä J, and Hakkola J (2019) Nutritional status modifies pregnane X receptor regulated transcriptome. *Sci Rep* **9**:16728.
- Hassani-Nezhad-Gashti F, Rysä J, Kummu O, Näpänkangas J, Bulmer M, Karpale M, Hukkanen J, and Hakkola J (2018) Activation of nuclear receptor PXR impairs glucose tolerance and dysregulates GLUT2 expression and subcellular localization in liver. *Biochem Pharmacol* **148**:253–264.
- He J, Gao J, Xu M, Ren S, Stefanovic-Racic M, O'Doherty RM, and Xie W (2013) PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice. *Diabetes* **62**:1876–1887.
- Hoekstra M, Lammers B, Out R, Li Z, Van Eck M, and Van Berkel TJ (2009) Activation of the nuclear receptor PXR decreases plasma LDL-cholesterol levels and induces hepatic steatosis in LDL receptor knockout mice. *Mol Pharm* **6**:182–189.
- Hotamisligil GS (2006) Inflammation and metabolic disorders. *Nature* **444**:860–867.
- Hu H, Yokobori K, and Negishi M (2020) PXR phosphorylated at Ser350 transduces a glucose signal to repress the estrogen sulfotransferase gene in human liver cells and fasting signal in mouse livers. *Biochem Pharmacol* **180**:114197.
- Huang K, Mukherjee S, DesMarais V, Albanese JM, Rafti E, Draghi I, A, Maher LA, Khanna KM, Mani S, and Matson AP (2018) Targeting the PXR-TLR4 signaling pathway to reduce intestinal inflammation in an experimental model of necrotizing enterocolitis. *Pediatr Res* **83**:1031–1040.
- Iwamoto J, Saito Y, Honda A, Miyazaki T, Ikegami T, and Matsuzaki Y (2013) Bile acid malabsorption deactivates pregnane X receptor in patients with Crohn's disease. *Inflamm Bowel Dis* **19**:1278–1284.
- Jeffery TD and Richardson ML (2021) A review of the effectiveness of hibuscus for treatment of metabolic syndrome. *J Ethnopharmacol* **270**:113762.
- Jetter A and Kullak-Ublick GA (2020) Drugs and hepatic transporters: a review. *Pharmacol Res* **154**:104234.
- Jin J, Wahlang B, Thapa M, Head KZ, Hardesty JE, Srivastava S, Merchant ML, Rai SN, Prough RA, and Cave MC (2021) Proteomics and metabolic phenotyping define principal roles for the aryl hydrocarbon receptor in mouse liver. *Acta Pharm Sin B* **11**:3806–3819.
- Jinhua W, Ying Z, and Yuhua L (2020) PXR-ABC drug transporters/CYP-mediated ursolic acid transport and metabolism in vitro and vivo. *Arch Pharm (Weinheim)* **353**:e2000082.
- Kachaylo EM, Yarushkin AA, and Pustynyn VO (2012) Constitutive androstane receptor activation by 2,4,6-triphenyldioxane-1,3 suppresses the expression of the gluconeogenic genes. *Eur J Pharmacol* **679**:139–143.
- Kakizaki S, Takizawa D, Tojima H, Horiguchi N, Yamazaki Y, and Mori M (2011) Nuclear receptors CAR and PXR: therapeutic targets for cholestatic liver disease. *Front Biosci (Landmark Ed)* **16**:2988–3005.
- Karpale M, Kärjäjäkäi AJ, Kummu O, Gylling H, Hyötyläinen T, Orešić M, Tolonen A, Hautajärvi H, Savolainen MJ, Ala-Korpela M, et al. (2021) Activation of pregnane X receptor induces atherogenic lipids and PCSK9 by a SREBP2-mediated mechanism. *Br J Pharmacol* **178**:2461–2481.
- Kawai T, Autieri MV, and Scalia R (2021) Adipose tissue inflammation and metabolic dysfunction in obesity. *Am J Physiol Cell Physiol* **320**:C375–C391.
- Kim M, Jee SC, Kim KS, Kim HS, Yu KN, and Sung JS (2021) Quercetin and isorhamnetin attenuate benzo[a]pyrene-induced toxicity by modulating detoxification enzymes through the AhR and NRF2 signaling pathways. *Antioxidants* **10**:787.
- Kim S, Choi S, Dutta M, Asubonteng JO, Polunas M, Goedken M, Gonzalez FJ, Cui JY, and Gyamfi MA (2021) Pregnane X receptor exacerbates nonalcoholic fatty liver disease accompanied by obesity- and inflammation-prone gut microbiome signature. *Biochem Pharmacol* **193**:114698.
- Kinlaw WB, Church JL, Harmon J, and Mariash CN (1995) Direct evidence for a role of the “spot 14” protein in the regulation of lipid synthesis. *J Biol Chem* **270**:16615–16618.
- Kirchner S, Panserat S, Lim PL, Kaushik S, and Ferraris RP (2008) The role of hepatic, renal and intestinal gluconeogenic enzymes in glucose homeostasis of juvenile rainbow trout. *J Comp Physiol B* **178**:429–438.
- Klaassen CD and Aleksunes LM (2010) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. *Pharmacol Rev* **62**:1–96.
- Kliwer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterström RH, et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. *Cell* **92**:73–82.
- Kodama S, Koike K, Negishi M, and Yamamoto Y (2004) Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. *Mol Cell Biol* **24**:7931–7940.

- Kodama S, Moore R, Yamamoto Y, and Negishi M (2007) Human nuclear pregnane X receptor cross-talk with CREB to repress cAMP activation of the glucose-6-phosphatase gene. *Biochem J* **407**:373–381.
- Koutsouras I, Theocharis S, Patsouris E, and Giaginis C (2013) Pregnane X receptor (PXR) at the crossroads of human metabolism and disease. *Curr Drug Metab* **14**:341–350.
- Kühlbeck J, Niskanen J, and Honkakoski P (2020) Metabolism-disrupting chemicals and the constitutive androstane receptor CAR. *Cells* **9**:E2306.
- Lee YS and Olefsky J (2021) Chronic tissue inflammation and metabolic disease. *Genes Dev* **35**:307–328.
- Li D, Mackowiak B, Brayman TG, Mitchell M, Zhang L, Huang SM, and Wang H (2015) Genome-wide analysis of human constitutive androstane receptor (CAR) transcriptome in wild-type and CAR-knockout HepaRG cells. *Biochem Pharmacol* **98**:190–202.
- Li H, Wang YG, Ma ZC, Yun-Hang G, Ling S, Teng-Fei C, Guang-Ping Z, and Gao Y (2021) A high-throughput cell-based gaussia luciferase reporter assay for measurement of CYP1A1, CYP2B6, and CYP3A4 induction. *Xenobiotica* **51**:752–763.
- Li M, Lan L, Zhang S, Xu Y, He W, Xiang D, Liu D, Ren X, and Zhang C (2021) IL-6 downregulates hepatic carboxylesterases via NF- κ B activation in dextran sulfate sodium-induced colitis. *Int Immunopharmacol* **99**:107920.
- Li T, Chen W, and Chiang JY (2007) PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. *J Lipid Res* **48**:373–384.
- Li T and Chiang JY (2014) Bile acid signaling in metabolic disease and drug therapy. *Pharmacol Rev* **66**:948–983.
- Li X, Li S, Chen M, Wang J, Xie B, and Sun Z (2018) (-)-Epigallocatechin-3-gallate (EGCG) inhibits starch digestion and improves glucose homeostasis through direct or indirect activation of PXR/CAR-mediated phase II metabolism in diabetic mice. *Food Funct* **9**:4651–4663.
- Li YH, Yeh HI, Jeng JS, and Chang MJ (2018) Comparison of the 2017 Taiwan lipid guidelines and the Western lipid guidelines for high risk patients. *J Chin Med Assoc* **81**:853–859.
- Lin YH, Luck H, Khan S, Schneeberger PHH, Tsai S, Clemente-Casares X, Lei H, Leu YL, Chan YT, Chen HY, et al. (2019) Aryl hydrocarbon receptor agonist indigo protects against obesity-related insulin resistance through modulation of intestinal and metabolic tissue immunity. *Int J Obesity* **43**:2407–2421.
- Lin YN, Chang HY, Wang CCN, Chu FY, Shen HY, Chen CJ, and Lim YP (2018) Oleanolic acid inhibits liver X receptor alpha and pregnane X receptor to attenuate ligand-induced lipogenesis. *J Agric Food Chem* **66**:10964–10976.
- Ling Z, Shu N, Xu P, Wang F, Zhong Z, Sun B, Li F, Zhang M, Zhao K, Tang X, et al. (2016) Involvement of pregnane X receptor in the impaired glucose utilization induced by atorvastatin in hepatocytes. *Biochem Pharmacol* **100**:98–111.
- Lu Q, Jiang C, Hou J, Qian H, Chu F, Zhang W, Ye M, Chen Z, Liu J, Yao H, et al. (2021) Patchouli alcohol modulates the pregnancy X receptor/Toll-like receptor 4/nuclear factor kappa B axis to suppress osteoclastogenesis. *Front Pharmacol* **12**:684976.
- Lynch C, Pan Y, Li L, Heyward S, Moeller T, Swaan PW, and Wang H (2014) Activation of the constitutive androstane receptor inhibits gluconeogenesis without affecting lipogenesis or fatty acid synthesis in human hepatocytes. *Toxicol Appl Pharmacol* **279**:33–42.
- Ma X, Idle JR, and Gonzalez FJ (2008) The pregnane X receptor: from bench to bedside. *Expert Opin Drug Metab Toxicol* **4**:895–908.
- Ma Y and Liu D (2012) Activation of pregnane X receptor by pregnenolone 16 α -carbonitrile prevents high-fat diet-induced obesity in AKR/J mice. *PLoS One* **7**:e38734.
- Mackowiak B and Wang H (2016) Mechanisms of xenobiotic receptor activation: direct vs. indirect. *Biochim Biophys Acta* **1859**:1130–1140.
- Makishima M (2005) Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. *J Pharmacol Sci* **97**:177–183.
- Marmugi A, Lukowicz C, Lasserre F, Montagner A, Polizzi A, Ducheix S, Goron A, Gamet-Payrastré L, Gerbal-Chaloin S, Pascussi JM, et al. (2016) Activation of the constitutive androstane receptor induces hepatic lipogenesis and regulates Pnpla3 gene expression in a LXR-independent way. *Toxicol Appl Pharmacol* **303**:90–100.
- Meng Z, Gwag T, Sui Y, Park SH, Zhou X, and Zhou C (2019) The atypical antipsychotic quetiapine induces hyperlipidemia by activating intestinal PXR signaling. *JCI Insight* **4**:e125657.
- Mescher M, Tigges J, Rolfes KM, Shen AL, Yee JS, Vogley C, Krutmann J, Bradfield CA, Lang D, and Haarmann-Stemmann T (2019) The Toll-like receptor agonist imiquimod is metabolized by aryl hydrocarbon receptor-regulated cytochrome P450 enzymes in human keratinocytes and mouse liver. *Arch Toxicol* **93**:1917–1926.
- Miao J, Fang S, Bae Y, and Kemper JK (2006) Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1 α . *J Biol Chem* **281**:14537–14546.
- Modica S, Bellafante E, and Moschetta A (2009) Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio. *Front Biosci* **14**:4719–4745.
- Moore LB, Parks DJ, Jones SA, Bledsoe RK, Conslor TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, et al. (2000) Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. *J Biol Chem* **275**:15122–15127.
- Moore MC, Coate KC, Winnick JJ, An Z, and Cherrington AD (2012) Regulation of hepatic glucose uptake and storage in vivo. *Adv Nutr* **3**:286–294.
- Moreau A, Têruec C, Beylot M, Albalea V, Tamasi V, Umbdenstock T, Parmentier Y, Sa-Cunha A, Suc B, Fabre JM, et al. (2009) A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. *Hepatology* **49**:2068–2079.
- Moreau A, Villarem MJ, Maurel P, and Pascussi JM (2008) Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. *Mol Pharm* **5**:35–41.
- Murray IA, Patterson AD, and Perdew GH (2014) Aryl hydrocarbon receptor ligands in cancer: friend and foe. *Nat Rev Cancer* **14**:801–814.
- Nakamura K, Moore R, Negishi M, and Sueyoshi T (2007) Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver. *J Biol Chem* **282**:9768–9776.
- Natividad JM, Agus A, Planchais J, Lamas B, Jarry AC, Martin R, Michel ML, Chong-Nguyen C, Roussel R, Straube M, et al. (2018) Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. *Cell Metab* **28**:737–749.e4.
- Negishi M (2017) Phenobarbital meets phosphorylation of nuclear receptors. *Drug Metab Dispos* **45**:532–539.
- Nieves KM, Hirota SA-O, and Flannigan KL (2022) Xenobiotic receptors and the regulation of intestinal homeostasis: harnessing the chemical output of the intestinal microbiota. *Am J Physiol Gastrointest Liver Physiol* **322**:G268–G281.
- Okamura M, Shizu R, Abe T, Kodama S, Hosaka T, Sasaki T, and Yoshinari K (2020) PXR functionally interacts with NF- κ B and AP-1 to downregulate the inflammation-induced expression of chemokine CXCL2 in mice. *Cells* **9**:E2296.
- Oladijeji PO and Chen T (2018) PXR: more than just a master xenobiotic receptor. *Mol Pharmacol* **93**:119–127.
- Oliverio F, Lukowicz C, Boussadia B, Forner-Piquer I, Pascussi JM, Marchi N, and Mselli-Lakhal L (2020) Constitutive androstane receptor: a peripheral and a neurovascular stress or environmental sensor. *Cells* **9**:E2426.
- Oshima M, Mimura J, Sekine H, Okawa H, and Fujii-Kuriyama Y (2009) SUMO modification regulates the transcriptional repressor function of aryl hydrocarbon receptor repressor. *J Biol Chem* **284**:11017–11026.
- Pavek P (2016) Pregnane X receptor (PXR)-mediated gene repression and cross-talk of PXR with other nuclear receptors via coactivator interactions. *Front Pharmacol* **7**:456.
- Petriello MC, Hoffman JB, Morris AJ, and Hennig B (2017) Emerging roles of xenobiotic detoxification enzymes in metabolic diseases. *Rev Environ Health* **32**:105–110.
- Philibert RA, Beach SR, and Brody GH (2012) Demethylation of the aryl hydrocarbon receptor repressor as a biomarker for nascent smokers. *Epigenetics* **7**:1331–1338.
- Postal BG, Ghezal S, Aguanno D, André S, Garbin K, Genser L, Brot-Laroche E, Poitou C, Soula H, Leturque A, et al. (2020) AhR activation defends gut barrier integrity against damage occurring in obesity. *Mol Metab* **39**:101007.
- Priyanka KD, Kotiya D, Rana M, Subbarao N, Puri N, and Tyagi RK (2016) Transcription regulation of nuclear receptor PXR: role of SUMO-1 modification and NDSM in receptor function. *Mol Cell Endocrinol* **420**:194–207.
- Qiu Z, Cervantes JL, Cicek BB, Mukherjee S, Venkatesh M, Maher LA, Salazar JC, Mani S, and Khanna KM (2016) Pregnane X receptor regulates pathogen-induced inflammation and host defense against an intracellular bacterial infection through Toll-like receptor 4. *Sci Rep* **6**:31936.
- Rana R, Coulter S, Kinyamu H, and Goldstein JA (2013) RBCK1, an E3 ubiquitin ligase, interacts with and ubiquitinates the human pregnane X receptor. *Drug Metab Dispos* **41**:398–405.
- Reddy RT and Nyunoya T (2021) Identification of novel pregnane X receptor (PXR) agonists by In silico and biological activity analyses and reversal of cigarette smoke-induced PXR downregulation. *Biochem Biophys Res Commun* **555**:1–6.
- Renu K, Sruthy KB, Parthiban S, Sugunapriyadarshini S, George A, Tirupathi Pichiah PB TP, Suman S, Gopalakrishnan AV, and Arunachalam S (2019) Elevated lipolysis in adipose tissue by doxorubicin via PPAR γ activation associated with hepatic steatosis and insulin resistance. *Eur J Pharmacol* **843**:162–176.
- Rey-Bedon C, Banik P, Gokaltun A, Hofheinz O, Yarmush ML, Uygun MK, and Usta OB (2022) CYP450 drug inducibility in NAFLD via an in vitro hepatic model: Understanding drug-drug interactions in the fatty liver. *Biomed Pharmacother* **146**:112377.
- Rochlani Y, Pothineni NV, Kovelamudi S, and Mehta JL (2017) Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. *Ther Adv Cardiovasc Dis* **11**:215–225.
- Rojas IY, Moyer BJ, Ringelberg CS, Wilkins OM, Pooler DB, Ness DB, Coker S, Tosteson TD, Lewis LD, Chamberlin MD, et al. (2021) Kynurenine-induced aryl hydrocarbon receptor signaling in mice causes body mass gain, liver steatosis, and hyperglycemia. *Obesity (Silver Spring)* **29**:337–349.
- Roth A, Looser R, Kaufmann M, Blättler SM, Rencurel F, Huang W, Moore DD, and Meyer UA (2008) Regulatory cross-talk between drug metabolism and lipid homeostasis: constitutive androstane receptor and pregnane X receptor increase Insig-1 expression. *Mol Pharmacol* **73**:1282–1289.
- Rothhammer V and Quintana FJ (2019) The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. *Nat Rev Immunol* **19**:184–197.
- Russell DW (2003) The enzymes, regulation, and genetics of bile acid synthesis. *Annu Rev Biochem* **72**:137–174.
- Rysä J, Buler M, Savolainen MJ, Ruskoaho H, Hakkola J, and Hukkanen J (2013) Pregnane X receptor agonists impair postprandial glucose tolerance. *Clin Pharmacol Ther* **93**:556–563.
- Safe S, Jin UH, Park H, Chapkin RS, and Jayaraman A (2020) Aryl hydrocarbon receptor (AHR) ligands as selective AHR modulators (SAHRMs). *Int J Mol Sci* **21**:E6654.
- Saklayen MG (2018) The global epidemic of the metabolic syndrome. *Curr Hypertens Rep* **20**:12.
- Salonurmi T, Nabil H, Ronkainen J, Hyötyläinen T, Hautajärvi H, Savolainen MJ, Tolonen A, Orešić M, Känkäkoski P, Rysä J, et al. (2020) β -hydroxycholesterol signals from the liver to regulate peripheral cholesterol transporters. *Front Pharmacol* **11**:361.
- Sayaf K, Zanutto I, Russo FP, Gabbia D, and De Martin S (2021) The nuclear receptor PXR in chronic liver disease. *Cells* **11**:61.
- Sberna AL, Assem M, Gautier T, Grober J, Guiu B, Jeannin A, Pais de Barros JP, Athias A, Lagrost L, and Masson D (2011) Constitutive androstane receptor activation stimulates faecal bile acid excretion and reverse cholesterol transport in mice. *J Hepatol* **55**:154–161.
- Sberna AL, Assem M, Xiao R, Ayers S, Gautier T, Guiu B, Deckert V, Chevriaux A, Grober J, Le Guern N, et al. (2011) Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice. *Arterioscler Thromb Vasc Biol* **31**:2232–2239.
- Schutz Y (2011) Protein turnover, ureagenesis and gluconeogenesis. *Int J Vitam Nutr Res* **81**:101–107.
- Scott C, Stokes R, Cha KM, Clouston A, Eslam M, Metwally M, Swarbrick MM, George J, and Guntton JE (2019) Myeloid cell deletion of aryl hydrocarbon receptor nuclear translocator (ARNT) induces non-alcoholic steatohepatitis. *PLoS One* **14**:e0225332.
- Shi Z, Lei H, Chen G, Yuan P, Cao Z, Ser HL, Zhu X, Wu F, Liu C, Dong M, et al. (2021) Impaired intestinal Akkermansia muciniphila and aryl hydrocarbon receptor ligands contribute to nonalcoholic fatty liver disease in mice. *mSystems* **6**:e00985-20.
- Shimizu T, Takagi C, Sawano T, Ejima Y, Nakatani J, Fujita T, and Tanaka H (2021) Indigo enhances wound healing activity of Caco-2 cells via activation of the aryl hydrocarbon receptor. *J Nat Med* **75**:833–839.
- Shinde R and McGaha TL (2018) The aryl hydrocarbon receptor: connecting immunity to the microenvironment. *Trends Immunol* **39**:1005–1020.
- Shizu R, Otsuka Y, Ezaki K, Ishii C, Arakawa S, Amaike Y, Abe T, Hosaka T, Sasaki T, Kanno Y, et al. (2020) Antiepileptic drug-activated constitutive androstane receptor inhibits peroxisome proliferator-activated receptor α and peroxisome proliferator-activated receptor γ coactivator 1 α -dependent gene expression to increase blood triglyceride levels. *Mol Pharmacol* **98**:634–647.

- Skoda J, Dohnalova K, Chalupsky K, Stahl A, Templin M, Maixnerova J, Micuda S, Grøntved L, Braeuning A, and Pavek P (2022) Off-target lipid metabolism disruption by the mouse constitutive androstane receptor ligand TCPOBOP in humanized mice. *Biochem Pharmacol* **197**:114905.
- Smutny T, Hysrova L, Braeuning A, Ingelman-Sundberg M, and Pavek P (2021) Transcriptional and post-transcriptional regulation of the pregnane X receptor: a rationale for interindividual variability in drug metabolism. *Arch Toxicol* **95**:11–25.
- Stejskalova L, Dvorak Z, and Pavek P (2011) Endogenous and exogenous ligands of aryl hydrocarbon receptor: current state of art. *Curr Drug Metab* **12**:198–212.
- Su X, Zhang M, Qi H, Gao Y, Yang Y, Yun H, Zhang Q, Yang X, Zhang Y, He J, et al. (2022) Gut microbiota-derived metabolite 3-iodoleacetic acid together with LPS induces IL-35⁺ B cell generation. *Microbiome* **10**:13.
- Sui Y, Helsley RN, Park SH, Song X, Liu Z, and Zhou C (2015) Intestinal pregnane X receptor links xenobiotic exposure and hypercholesterolemia. *Mol Endocrinol* **29**:765–776.
- Sui Y, Meng Z, Chen J, Liu J, Hernandez R, Gonzales MB, Gwag T, Morris AJ, and Zhou C (2021) Effects of dicyclohexyl phthalate exposure on PXR activation and lipid homeostasis in mice. *Environ Health Perspect* **129**:127001.
- Sui Y, Xu J, Rios-Pilier J, and Zhou C (2011) Deficiency of PXR decreases atherosclerosis in apoE-deficient mice. *J Lipid Res* **52**:1652–1659.
- Sultana H, Kato A, Ohashi A, Takashima R, Katsurai T, Sato S, Monma M, Ohsaki Y, Goto T, Komai M, et al. (2021) Effect of vitamin K-mediated PXR activation on drug-metabolizing gene expression in human intestinal carcinoma LS180 cell line. *Nutrients* **13**:1709.
- Tai TS, Tien N, Shen HY, Chu FY, Wang CCN, Lu CH, Yu HI, Kung FP, Chuang HH, Lee YR, et al. (2019) Sesamin, a naturally occurring lignan, inhibits ligand-induced lipogenesis through interaction with liver X receptor alpha (LXRα) and pregnane X receptor (PXR). *Evid Based Complement Alternat Med* **2019**:9401648.
- Theile D, Wagner L, Bay C, Haefeli WE, and Weiss J (2021) Time-resolved effect of interferon-alpha 2a on activities of nuclear factor kappa B, pregnane X receptor and on drug disposition genes. *Pharmaceutics* **13**:808.
- Thomas C, Pellicciari R, Pruzanski M, Auwerx J, and Schoonjans K (2008) Targeting bile-acid signalling for metabolic diseases. *Nat Rev Drug Discov* **7**:678–693.
- Tian FY, Hivert MF, Wen X, Xie C, Niu Z, Fan L, Gillman MW, and Chen WQ (2017) Tissue differences in DNA methylation changes at AHRR in full term low birth weight in maternal blood, placenta and cord blood in Chinese. *Placenta* **52**:49–57.
- Venkatesh M, Mukherjee S, Wang H, Li H, Sun K, Benechet AP, Qiu Z, Maher L, Redinbo MR, Phillips RS, et al. (2014) Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. *Immunity* **41**:296–310.
- Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC, Neuschwander-Tetri BA, Brunt EM, Guzelian PS, and Evans RM (2000) Humanized xenobiotic response in mice expressing nuclear receptor SXR. *Nature* **406**:435–439.
- Wang C, Xu W, Zhang Y, Huang D, and Huang K (2018) Poly(ADP-ribosyl)ated PXR is a critical regulator of acetaminophen-induced hepatotoxicity. *Cell Death Dis* **9**:819.
- Wang X, Wang F, Lu Z, Jin X, and Zhang Y (2018) Semi-quantitative profiling of bile acids in serum and liver reveals the dosage-related effects of dexamethasone on bile acid metabolism in mice. *J Chromatogr B Analyt Technol Biomed Life Sci* **1095**:65–74.
- Wang Y, Yutuc E, and Griffiths WJ (2021) Cholesterol metabolism pathways: are the intermediates more important than the products? *FEBS J* **288**:3727–3745.
- Wen J and Zhao M (2021) OATP1B1 plays an important role in the transport and treatment efficacy of sorafenib in hepatocellular carcinoma. *Dis Markers* **2021**:9711179.
- Xiang D, Chu T, Li M, Wang Q, and Zhu G (2018) Effects of pyrethroid pesticide cis-bifenthrin on lipogenesis in hepatic cell line. *Chemosphere* **201**:840–849.
- Xiang D and Wang Q (2021) PXR-mediated organophorous flame retardant tricesyl phosphate effects on lipid homeostasis. *Chemosphere* **284**:131250.
- Xiao L, Xie X, and Zhai Y (2010) Functional crosstalk of CAR-LXR and ROR-LXR in drug metabolism and lipid metabolism. *Adv Drug Deliv Rev* **62**:1316–1321.
- Xing Y, Yan J, and Niu Y (2020) PXR: a center of transcriptional regulation in cancer. *Acta Pharm Sin B* **10**:197–206.
- Xu CX, Wang C, Zhang ZM, Jaeger CD, Krager SL, Bottum KM, Liu J, Liao DF, and Tischkau SA (2015) Aryl hydrocarbon receptor deficiency protects mice from diet-induced adiposity and metabolic disorders through increased energy expenditure. *Int J Obes* **39**:1300–1309.
- Xu DX, Wei W, Sun MF, Wu CY, Wang JP, Wei LZ, and Zhou CF (2004) Kupffer cells and reactive oxygen species partially mediate lipopolysaccharide-induced downregulation of nuclear receptor pregnane x receptor and its target gene CYP3a in mouse liver. *Free Radic Biol Med* **37**:10–22.
- Xu H, Zhou S, Tang Q, Xia H, and Bi F (2020) Cholesterol metabolism: new functions and therapeutic approaches in cancer. *Biochim Biophys Acta Rev Cancer* **1874**:188394.
- Yan J, Chen B, Lu J, and Xie W (2015) Deciphering the roles of the constitutive androstane receptor in energy metabolism. *Acta Pharmacol Sin* **36**:62–70.
- Yan T, Luo Y, Xia Y, Hamada K, Wang Q, Yan N, Krausz KW, Ward JM, Hao H, Wang P, et al. (2021) St. John's Wort alleviates dextran sodium sulfate-induced colitis through pregnane X receptor-dependent NFκB antagonism. *FASEB J* **35**:e21968.
- Yang Y and Zhang J (2020) Bile acid metabolism and circadian rhythms. *Am J Physiol Gastrointest Liver Physiol* **319**:G549–G563.
- Ye N, Wang H, Hong J, Zhang T, Lin C, and Meng C (2016) PXR mediated protection against liver inflammation by ginkgolide A in tetrachloromethane treated mice. *Biomol Ther (Seoul)* **24**:40–48.
- Zhang J, Wei Y, Hu B, Huang M, Xie W, and Zhai Y (2013) Activation of human stearyl-coenzyme A desaturase 1 contributes to the lipogenic effect of PXR in HepG2 cells. *PLoS One* **8**:e67959.
- Zhao LY, Xu JY, Shi Z, Englert NA, and Zhang SY (2017) Pregnane X receptor (PXR) deficiency improves high fat diet-induced obesity via induction of fibroblast growth factor 15 (FGF15) expression. *Biochem Pharmacol* **142**:194–203.
- Zhao RX, He Q, Sha S, Song J, Qin J, Liu P, Sun YJ, Sun L, Hou XG, and Chen L (2020) Increased AHR transcripts correlate with pro-inflammatory T-helper lymphocytes polarization in both metabolically healthy obesity and type 2 diabetic patients. *Front Immunol* **11**:1644.
- Zhou C (2016) Novel functions of PXR in cardiometabolic disease. *Biochim Biophys Acta* **1859**:1112–1120.
- Zhou C, King N, Chen KY, and Breslow JL (2009) Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice. *J Lipid Res* **50**:2004–2013.
- Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, Lee JH, Khadem S, Ren S, Li S, et al. (2008) Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. *Gastroenterology* **134**:556–567.
- Zhu XY, Xia HG, Wang ZH, Li B, Jiang HY, Li DL, Jin R, and Jin Y (2020) In vitro and in vivo approaches for identifying the role of aryl hydrocarbon receptor in the development of nonalcoholic fatty liver disease. *Toxicol Lett* **319**:85–94.
- Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, Birner-Gruenberger R, Riederer M, Lass A, Neuberger G, Eisenhaber F, Hermetter A, et al. (2004) Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. *Science* **306**:1383–1386.

Address correspondence to: Yanping Li, Laboratory of Clinical Pharmacy and Adverse Drug Reaction, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China. E-mail: liyanping_512@163.com; or Jinhan He, Department of Pharmacy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, China. E-mail: jinhanhe@scu.edu.cn